OR2D2

Across TCGA pan-cancer cohorts, OR2D2 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated OR2D2 data layer compared with 4 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR2D2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2D2 expression acts as an unfavorable survival marker.

LIHC, BLCA, and UCS are the cancer types where OR2D2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.318	0.559	<.001	57	view →
BLCA	DFS	Tertile	All	0.219	0.533	.003	54	view →
UCS	DFS	Tertile	IV	0.230	0.767	.009	36	view →
UVM	OS	Tertile	All	0.218	0.696	.014	36	view →
SKCM	DFS	Tertile	II,III,IV	0.399	0.739	<.001	36	view →
UCEC	OS	Tertile	IV	0.190	0.514	.006	36	view →
TGCT	DFS	Tertile	All	0.605	0.847	.001	30	view →
READ	DFS	Tertile	IV	0.168	0.640	<.001	27	view →
ACC	DFS	Tertile	IV	0.010	0.383	<.001	27	view →
THCA	DFS	Tertile	All	0.839	0.925	.006	24	view →
STAD	DFS	Median	II,III,IV	0.522	0.671	.007	18	view →
LUAD	DFS	Tertile	IV	0.333	0.671	.048	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

OR2D2–LIHC (DFS)

Open the LIHC breakdown →